Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Randomized Multicenter Phase II Trial of intensified neoadjuvant chemotherapy in locally advanced pancreatic cancer
2013-004796-12Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- May 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of paclitaxel, gemcitabine, irinotecan, oxaliplatin, folinic acid and 1 more in pancreatic cancer (PC) and Pancreatic carcinoma (PC) (2 arms), sponsored by AIO-Studien. Primary endpoint: Curative-intent pancreatic resection rate after intensified neoadjuvant chemotherapy. Started May 2014; status: completed.
02
Drugs
paclitaxelgemcitabineirinotecanoxaliplatinfolinic acid
03
Conditions
pancreatic cancer (PC)Pancreatic carcinoma (PC)
Beyond the preview
Go deeper on 2013-004796-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004796-12.